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From 1987 to the present our Cuban Centre
has performed more than 30 foetal nigral
transplants to the striatum in patients with
Parkinson’s disease. To study the improvement
reported in dopaminergic drug response and the
decrease L-Dopa daily dose together with better
motor performance /1/, the present pharmaco-
logical trial was applied to four Parkinsonian
patients, who underwent stereotactic implan-
tations of foetal ventral mesencephalon dis-
sociated cells.
Four male patients with idiopathic Parkin-
son’s disease were studied during their hospital-
ization (approximately one year). They were
diagnosed and followed clinically according to
the CAPIT recommendations.
Using stereotactic technique we performed
computer-assisted CT-guided transplantation of
foetal mesencephalic cell suspensions to the
right striatum of the four patients.
The clinical evolution was evaluated by a
single L-Dopa response test and the apomor-
phine dose-response curve (using 1 mg to 4 mg)
before, and 30, 60 and 90 days after surgery.
Biochemical studies included the measurement
of L-Dopa, 3-O-methyl-dopa and catecholamine
catabolites in CSF by HPLC pre-operatively and
60 days after the implant. Statistical analyses
were performed by Wilcoxon paired rank test
and lineal correlation methods.
Changes in the rates of the response (increase
of "on" phase duration and decrease in "on"
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latency) were observed in the single dose L-
Dopa test, together with a decreased magnitude
of the response, at 90 days after implants
(P<0.05). All patients showed bilateral im-
provement but asymmetrically, better on the left
side. Also reduction of dyskinesias was observed.
These effects were similar to the apomorphine
dose-response test; in fact, this is closely dose-
correlated in patient number four (CR:0.68).
The most significant improvement was an im-
proved motor performance during baseline
("off’ phase).
CSF levels ofDOPAC were increased 60 days
after nigral implants and the levels of HVA in
the CSF were higher in response to the same
dose ofL-Dopa (250 nag madopar).
In summary, different patterns of response to
dopaminergic drugs after the implant, charac-
terized by shorter latency, a larger "on" phase,
reduced magnitude of response, lack of signifi-
cant dyskinesias, better motor performance in
basal "off’, and higher increments of HVA in
CSF in response to L-Dopa, developed in our
patients, similarly to Parkinsonian patients with
short-term L-Dopa therapy.
These data support the hypothesis that trans-
plants induce the restoration of dopaminergic
pathways.
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